Dr. DeFronzo: The Most Powerful (and Cheap) Therapy for Diabetes Recovery

Physionic

Apr 9, 2025

Episode description

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

*HEALTH AUTONOMY [COURSE]*
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

*JOIN THE COMMUNITY*
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

*EMAIL LIST*
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

*HIRE ME FOR CONSULTING:*
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
0:45 - Understanding Triple Therapy
4:14 - The Claims...
6:44 - What does the EDICT study actually show?
12:27 - Important Points
13:47 - Main Points

Reference
[Study 434] Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care. 2021;44(2):433-439. doi:10.2337/dc20-0978

Funding/Conflicts: Public Funding [National Institutes of Health (grant R01DK24092-34); Exenatide was provided by AstraZeneca] // Potential direct Conflicts of Interest [Dr. Ralph A. DeFronzo receives grant support from Janssen, Merck, and AstraZeneca, serves on advisory boards for AstraZeneca, Janssen Pharmaceuticals, Boehringer Ingelheim, Intarcia, and Novo Nordisk, participates in speakers bureaus for Novo Nordisk and AstraZeneca; Dr. Eugenio Cersosimo receives grant support from AstraZeneca and Janssen Pharmaceuticals, serves on advisory boards for VeroScience, the Boehringer Ingelheim and Lilly Diabetes Alliance, and Sanofi, participates in speakers bureaus for AstraZeneca, Janssen Pharmaceuticals, and the Boehringer Ingelheim and Lilly Diabetes Alliance, and other authors reported no potential conflicts of interest related to this article.]

********CRITIQUES, RULES, AND NOTES********

Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).

Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:

Be mindful that this content is not all encompassing on the subject at hand and is self-limited for brevity to reach a wider audience. Also, be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.

RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.

If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it (thank you!).

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

#reversingdiabetes #diabetesmanagement

Episode description

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

*HEALTH AUTONOMY [COURSE]*
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

*JOIN THE COMMUNITY*
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

*EMAIL LIST*
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

*HIRE ME FOR CONSULTING:*
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
0:45 - Understanding Triple Therapy
4:14 - The Claims...
6:44 - What does the EDICT study actually show?
12:27 - Important Points
13:47 - Main Points

Reference
[Study 434] Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care. 2021;44(2):433-439. doi:10.2337/dc20-0978

Funding/Conflicts: Public Funding [National Institutes of Health (grant R01DK24092-34); Exenatide was provided by AstraZeneca] // Potential direct Conflicts of Interest [Dr. Ralph A. DeFronzo receives grant support from Janssen, Merck, and AstraZeneca, serves on advisory boards for AstraZeneca, Janssen Pharmaceuticals, Boehringer Ingelheim, Intarcia, and Novo Nordisk, participates in speakers bureaus for Novo Nordisk and AstraZeneca; Dr. Eugenio Cersosimo receives grant support from AstraZeneca and Janssen Pharmaceuticals, serves on advisory boards for VeroScience, the Boehringer Ingelheim and Lilly Diabetes Alliance, and Sanofi, participates in speakers bureaus for AstraZeneca, Janssen Pharmaceuticals, and the Boehringer Ingelheim and Lilly Diabetes Alliance, and other authors reported no potential conflicts of interest related to this article.]

********CRITIQUES, RULES, AND NOTES********

Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).

Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:

Be mindful that this content is not all encompassing on the subject at hand and is self-limited for brevity to reach a wider audience. Also, be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.

RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.

If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it (thank you!).

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

#reversingdiabetes #diabetesmanagement

Mindsip insights from this episode:

Choose triple therapy for lower failure rates in treatment

In the study, the triple therapy had a failure rate of around 33%, which was significantly better than the conventional therapy's failure rate of nearly 60%.

Implement combination therapy for complex diseases like diabetes

Dr. DeFronzo's philosophy is that if a disease has multiple underlying problems, like the eight identified in diabetes, it should be treated with a combination of drugs from the start.

Implement EDICT study's triple therapy for effective management

The EDICT study's triple therapy consists of metformin, exenatide (an early GLP-1 agonist), and pioglitazone, which are all relatively inexpensive drugs.

Utilize pioglitazone to reduce inflammation and enhance glucose uptake

The drug pioglitazone is a PPAR Gamma activator that not only helps cells take in glucose but also binds to and represses inflammation genes.

Reform 'treat to fail' model in diabetes care

The conventional ADA approach is described as a 'treat to fail' method, where you start with metformin and only add more drugs after the initial treatment stops working.

Implement triple therapy to enhance insulin sensitivity

The primary advantage of the triple therapy is that it causes a huge improvement in insulin sensitivity, while the standard ADA approach results in zero improvement.

Prioritize triple therapy for effectiveness, regardless of weight change

The triple therapy outperformed the conventional therapy regardless of whether a person lost or gained weight over the three-year study period.

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius